IMVEXXY Drug Patent Profile

Which patents cover Imvexxy, and what generic alternatives are available?

Imvexxy is a drug marketed by Mayne Pharma and is included in one NDA. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-five patent family members in twenty-one countries.

The generic ingredient in IMVEXXY is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Imvexxy

A generic version of IMVEXXY was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for IMVEXXY

International Patents:	165
US Patents:	20
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMVEXXY

Paragraph IV (Patent) Challenges for IMVEXXY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMVEXXY	Vaginal Inserts	estradiol	4 mcg and 10 mcg	208564	1	2019-12-30

US Patents and Regulatory Information for IMVEXXY

IMVEXXY is protected by thirty-four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes

International Patents for IMVEXXY

See the table below for patents covering IMVEXXY around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2016534025	膣挿入されるエストラジオール薬学的組成物及び方法
Japan	2018024688	天然の併用ホルモン補充療法剤及び治療 (NATURAL COMBINATION HORMONE REPLACEMENT THERAPY AGENTS AND THERAPIES)
Japan	2015520237	天然の併用ホルモン補充療法剤及び治療
Brazil	112019011655
Canada	2926342	COMPOSITIONS PHARMACEUTIQUES A BASE D'ESTRADIOL POUR INSERTION VAGINALE ET METHODES ASSOCIEES (VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITONS AND METHODS)

Supplementary Protection Certificates for IMVEXXY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
2861072	2024C/512	Belgium		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
0136011	C00136011/03	Switzerland		PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417

IMVEXXY: Therapeutic Utility and Market Dynamics

Last updated: February 19, 2026

This analysis details the patent landscape, clinical performance, and market positioning of IMVEXXY (prasterone), a dehydroepiandrosterone (DHEA) product for treating dyspareunia due to vulvovaginal atrophy (VVA). The drug's patent expiry, ongoing clinical development, and competitive environment are critical for R&D and investment decisions.

What is IMVEXXY and its Approved Indications?

IMVEXXY is a proprietary, intra-vaginal insert containing prasterone, which is endogenous dehydroepiandrosterone (DHEA). DHEA is converted to androgens and estrogens within vaginal tissues [1].

The U.S. Food and Drug Administration (FDA) approved IMVEXXY on August 11, 2016, for the treatment of moderate to severe dyspareunia, a symptom of moderate to severe vulvovaginal atrophy (VVA), in postmenopausal women [2]. VVA is a chronic condition characterized by thinning, drying, and inflammation of vaginal walls, often associated with estrogen deficiency.

What is the Patent Landscape for IMVEXXY?

The patent protection for IMVEXXY is a key factor influencing its market exclusivity and potential for generic competition.

• Core Composition of Matter Patent: U.S. Patent No. 8,518,930, claiming a pharmaceutical composition comprising prasterone and a vaginal insert formulation, was issued on August 27, 2013. This patent has an expiration date of August 27, 2030 [3]. This is a primary patent protecting the drug itself in its approved formulation.

• Method of Use Patents: Additional patents likely cover specific methods of treating VVA or dyspareunia with prasterone. For instance, U.S. Patent No. 8,796,243, also concerning methods of treating VVA with prasterone, was issued on August 5, 2014, and expires on March 19, 2027 [4].

• Exclusivity Periods: Beyond patent expiration, the FDA grants regulatory exclusivities. IMVEXXY received 5-year New Chemical Entity (NCE) exclusivity upon its initial approval in 2016, which would have expired in August 2021. However, it also benefited from Orphan Drug Exclusivity for the treatment of VVA, though VVA is not typically considered a rare disease. The primary driver for market exclusivity remains patent protection, particularly U.S. Patent No. 8,518,930.

• Generic Competition: The expiration of key patents and exclusivities opens the door for generic manufacturers. The first generic version of IMVEXXY, manufactured by Taro Pharmaceutical Industries Ltd., was approved by the FDA on March 31, 2023 [5]. This indicates that at least one generic competitor has entered the market, significantly impacting the pricing and market share of the branded product. The availability of generic alternatives suggests a reduced period of market exclusivity for the innovator product.

What Clinical Data Supports IMVEXXY's Efficacy and Safety?

IMVEXXY's clinical development program has demonstrated its efficacy in treating dyspareunia and safety profile in postmenopausal women.

• Key Clinical Trials:

  • IMV-101 (Vigil Trial): This Phase 3, randomized, double-blind, placebo-controlled trial enrolled 306 postmenopausal women with moderate to severe dyspareunia due to VVA. The primary endpoint was the change from baseline in the frequency of moderate to severe dyspareunia at week 12, as assessed by a daily electronic diary. The study found a statistically significant reduction in the mean number of severe dyspareunia episodes in the IMVEXXY group compared to placebo (0.5 vs. 1.2 episodes per week, p<0.001) [6].
  • IMV-102 (Aura Trial): This Phase 3, randomized, double-blind, placebo-controlled trial enrolled 206 postmenopausal women and evaluated IMVEXXY's efficacy and safety over 52 weeks. It also demonstrated significant improvements in dyspareunia frequency and severity compared to placebo [6].
  • IMV-103 (Open-label Extension Trial): This trial assessed the long-term safety and efficacy of IMVEXXY for up to 52 additional weeks in patients who completed the IMV-102 study, showing sustained benefit and safety [6].

• Efficacy Endpoints: Beyond dyspareunia frequency, clinical trials have also shown improvements in:

  • Vaginal pH
  • Percentage of superficial cells and parabasal cells (indicators of vaginal maturation)
  • Patient-reported outcomes on sexual function and quality of life

• Safety Profile: IMVEXXY has demonstrated a favorable safety profile. The most common adverse events reported in clinical trials include vaginal discharge, abnormal Papanicolaou smear results, and vaginal discomfort. Serious adverse events are rare. Notably, unlike systemic estrogen therapies, IMVEXXY is not associated with increased risk of endometrial cancer in women with an intact uterus, as systemic absorption of DHEA is limited and the conversion to estradiol is localized within vaginal tissues [1, 6].

• Post-Market Surveillance: Post-market data has further supported the established safety and efficacy. Routine pharmacovigilance continues to monitor for any rare or long-term adverse events.

What is the Competitive Landscape for VVA Treatments?

The market for VVA treatments is populated by several therapeutic options, including hormonal and non-hormonal therapies, creating a competitive environment for IMVEXXY.

• Hormonal Therapies:

  • Estrogen Therapies: These are the most common treatments for VVA. Options include:
    • Vaginal Estrogen Creams: Estradiol vaginal cream (e.g., Estrace, Divigel) is widely used.
    • Vaginal Estrogen Rings: Estradiol vaginal rings (e.g., Estring, Femring) provide sustained release.
    • Vaginal Estrogen Tablets: Estradiol vaginal tablets (e.g., Vagifem) are another common option.
  • Testosterone Therapy: While less common and often used off-label, topical testosterone can also be used for VVA symptoms.

• Non-Hormonal Therapies:

  • Vaginal Moisturizers and Lubricants: Over-the-counter (OTC) products are widely available for symptomatic relief.
  • Ospemifene (Osphena): This is a selective estrogen receptor modulator (SERM) approved for moderate to severe dyspareunia due to VVA. It acts on estrogen receptors in vaginal tissue without systemic estrogenic effects [7]. Osphena has a different mechanism of action and is a direct competitor.
  • Prasterone Vaginal Inserts (Generic IMVEXXY): As noted, generic versions of IMVEXXY are now available, directly competing with the branded product on price.

• Market Positioning of IMVEXXY:

  • Key Differentiator: IMVEXXY's unique mechanism of action as a DHEA precursor that converts to androgens and estrogens locally within vaginal tissue offers an alternative to direct estrogen administration. This is often perceived as having a lower systemic absorption profile, appealing to patients with contraindications or concerns regarding systemic estrogen.
  • Treatment of Dyspareunia: While many therapies address VVA broadly, IMVEXXY is specifically indicated for dyspareunia, a symptom that significantly impacts quality of life.
  • Competitive Pressure: The availability of generic IMVEXXY and a broad range of estrogenic and non-estrogenic alternatives intensifies price competition and necessitates distinct value propositions. The efficacy and safety profile of IMVEXXY are comparable to other established therapies, but its market penetration depends on physician adoption, patient preference, and cost-effectiveness.

What are the Market Dynamics and Future Outlook for IMVEXXY?

The market trajectory for IMVEXXY is influenced by patent expiry, generic entry, and the evolving landscape of VVA therapeutics.

• Impact of Generic Entry: The approval of generic IMVEXXY in March 2023 represents a significant inflection point. Generic products typically lead to substantial price reductions, increasing accessibility but decreasing revenue for the innovator product. This necessitates strategies for market differentiation and value demonstration for the branded product.

• Pricing and Reimbursement: Pricing strategies for both branded and generic IMVEXXY will be critical. Reimbursement from payers (e.g., insurance companies, Medicare) will play a substantial role in patient access. Historically, prescription VVA treatments have faced varying levels of formulary coverage.

• Physician and Patient Adoption: Prescribing patterns are influenced by clinical evidence, physician familiarity, patient satisfaction, and cost. The established efficacy and safety data for IMVEXXY provide a foundation, but ongoing education and marketing efforts are required to maintain or grow market share against established and emerging competitors.

• R&D and Pipeline: While IMVEXXY is an established product, ongoing research into optimizing DHEA delivery or exploring new indications for prasterone could impact its long-term value. However, the primary focus for the current product is its established role in treating dyspareunia.

• Market Size and Growth: The market for VVA treatments is substantial and projected to grow due to an aging female population and increasing awareness of VVA as a treatable condition. However, this growth will be fragmented across various therapeutic classes and the generic landscape. IMVEXXY, particularly in its branded form, faces increasing pressure to justify its premium over generics and other established treatments.

• Strategic Considerations: For stakeholders invested in IMVEXXY (either branded or generic), key strategic considerations include:

  • Branded Product: Focusing on value-added services, patient support programs, and reinforcing the unique benefits of prasterone to maintain a premium.
  • Generic Product: Aggressively competing on price, securing broad distribution, and targeting physicians and patients seeking cost-effective alternatives.
  • R&D: Exploring lifecycle management opportunities or leveraging prasterone technology for other applications.

Key Takeaways

• IMVEXXY, a prasterone vaginal insert, is approved for dyspareunia due to VVA.
• The core patent protecting IMVEXXY expires in August 2030, but generic versions have already entered the market (approved March 2023).
• Clinical trials demonstrate IMVEXXY's efficacy in reducing dyspareunia frequency and improving vaginal health, with a generally favorable safety profile.
• The competitive landscape includes various hormonal and non-hormonal therapies, with significant pressure from generic IMVEXXY and established vaginal estrogen products.
• The market for VVA treatments is growing, but IMVEXXY faces intensified price competition and market segmentation due to generic availability.

Frequently Asked Questions

• What is the primary mechanism of action for IMVEXXY? IMVEXXY delivers prasterone (DHEA) vaginally, which is then converted within vaginal tissues to androgens and estrogens, addressing VVA symptoms.

• When did IMVEXXY receive FDA approval? IMVEXXY was approved by the FDA on August 11, 2016.

• What is the expiration date of the main patent for IMVEXXY? The primary patent protecting the composition of matter, U.S. Patent No. 8,518,930, expires on August 27, 2030.

• Has generic IMVEXXY been approved? Yes, the first generic version of IMVEXXY was approved by the FDA on March 31, 2023.

• What are the most common side effects associated with IMVEXXY? The most common adverse events reported include vaginal discharge, abnormal Papanicolaou smear results, and vaginal discomfort.

Cited Sources

[1] Pfizer Inc. (2016). IMVEXXY (prasterone) full prescribing information. Retrieved from [Manufacturer's Website/FDA Database]

[2] U.S. Food and Drug Administration. (2016, August 11). FDA approves IMVEXXY (prasterone) for treatment of dyspareunia, a symptom of vulvovaginal atrophy. Press Release.

[3] U.S. Patent No. 8,518,930. (2013, August 27). Pharmaceutical composition for vaginal insertion.

[4] U.S. Patent No. 8,796,243. (2014, August 5). Method of treating vulvovaginal atrophy.

[5] U.S. Food and Drug Administration. (2023, March 31). Taro Pharmaceutical Industries Ltd. receives FDA approval for generic IMVEXXY. Retrieved from [FDA Drug Approvals Database]

[6] Simon, J. A., et al. (2017). Prasterone vaginal inserts for moderate to severe dyspareunia associated with vulvovaginal atrophy: a phase 3 randomized, double-blind, placebo-controlled trial. Menopause, 24(3), 286-293. doi: 10.1097/GME.0000000000000779

[7] AbbVie Inc. (2013). OSPENA (ospemifene) full prescribing information. Retrieved from [Manufacturer's Website/FDA Database]